Clostridioides Difficile Infection
VIDEO: Rebyota safe, effective when given via colonoscopy for recurrent C. difficile
CHICAGO — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses data showing consistent safety and efficacy of Rebyota when administered via colonoscopy for prevention of recurrent Clostridioides difficile infection.
Mandatory ID approval associated with improved C. difficile testing
An intervention requiring that infectious diseases approve testing for Clostridioides difficile infection increased the appropriateness of testing for hospital-onset C. difficile and lowered the positive testing rate by more than 50%.
Highlights from DDW 2023
In this episode of Meeting Mic, we bring you Healio’s top headlines from DDW 2023.
Linezolid safe, effective for treating necrotizing soft tissue infections
Treating patients with necrotizing soft tissue infections with either clindamycin plus vancomycin or linezolid resulted in similar clinical outcomes, according to a study published in Open Forum Infectious Diseases.
VIDEO: ‘We can feel confident’ in Rebyota for recurrent C. difficile in high-risk patients
CHICAGO — In a Healio video exclusive, Glenn S. Tillotson, MSc, PhD, discusses the safety and sustained efficacy of Rebyota at 6 months for recurrent Clostridioides difficile infection in patients with immunocompromising conditions.
VIDEO: Low risk for congestive heart failure exacerbation with Zinplava for C. difficile
CHICAGO — In this Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, recaps results from a real-world analysis of Zinplava for prevention of recurrent Clostridioides difficile infection in patients with congestive heart failure.
VIDEO: No change in concomitant medications after Rebyota for recurrent C. difficile, IBD
CHICAGO — Treatment with Rebyota did not affect concurrent medication use in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection, Jessica R. Allegretti, MD, MPH, explains in this Healio video.
C. difficile infection recurrence after FMT higher than previously reported in IBD
CHICAGO — More than 20% of patients with inflammatory bowel disease experienced recurrent Clostridioides difficile infection 1 year after fecal microbiota transplantation, according to data presented at Digestive Disease Week.
C. difficile colonization associated with CDI development among patients in the ICU
Patients in the ICU with Clostridioides difficile colonization, histories of inflammatory bowel disease and longer ICU stays had an increased risk for developing C. difficile infection, according to a study in Infection Control & Hospital Epidemiology.
ASH recognizes Choosing Wisely, Guideline Implementation champions
ASH recognized three Choosing Wisely champions and three guideline implementation champions at this year’s ASH Annual Meeting and Exposition.